PAI-1, hematopoietic stem cell, and chronic myeloid leukemia.
1/5 보강
The new treatment goal for chronic myeloid leukemia (CML) is treatment-free remission, which requires the achievement and maintenance of a deep molecular response (DMR) using a tyrosine kinase inhibit
APA
Takahashi N, Harigae H (2026). PAI-1, hematopoietic stem cell, and chronic myeloid leukemia.. Biomedical journal, 49(1), 100854. https://doi.org/10.1016/j.bj.2025.100854
MLA
Takahashi N, et al.. "PAI-1, hematopoietic stem cell, and chronic myeloid leukemia.." Biomedical journal, vol. 49, no. 1, 2026, pp. 100854.
PMID
40254273
Abstract
The new treatment goal for chronic myeloid leukemia (CML) is treatment-free remission, which requires the achievement and maintenance of a deep molecular response (DMR) using a tyrosine kinase inhibitor (TKI). However, only a limited number of patients achieve or maintain DMR. TM5614, a PAI1 inhibitor, can bring quiescent hematopoietic stem cells from the bone marrow niche into the cell cycle. Thus, the combination of TM5614 and TKI may eradicate CML cells. Currently, a phase III clinical trial is confirming the efficacy of TM5614 and TKI combination therapy.
MeSH Terms
Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hematopoietic Stem Cells; Plasminogen Activator Inhibitor 1; Protein Kinase Inhibitors
같은 제1저자의 인용 많은 논문 (5)
- Influence of pharmacokinetics-related polymorphisms on asciminib exposure in patients with Japanese chronic myeloid leukemia.
- [The challenge of achieving treatment-free remission for chronic myeloid leukemia].
- Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan.
- Human peritoneal CCR2CRIg macrophage subset exhibits embryonic origin-like phenotypes.
- Efficacy of perioperative pembrolizumab for triple-negative breast cancer with apocrine feature or metaplastic carcinoma.